ArriVent BioPharma, Inc. (AVBP) vs 4D Molecular Therapeutics, Inc. (FDMT)
A side-by-side comparison of ArriVent BioPharma, Inc. and 4D Molecular Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVBP
ArriVent BioPharma, Inc.
$15.54HealthcareDelayed quote: Oct 6, 2026, 1:10 PM EDT
FDMT
4D Molecular Therapeutics, Inc.
$12.68HealthcareDelayed quote: Oct 6, 2026, 1:10 PM EDT
Total return — AVBP vs FDMT
growth of $100 · dividends reinvested · last 3yAVBP +42.3% (+12.5%/yr)FDMT -26.2% (-9.6%/yr)AVBP compounded faster over this window
AVBP FDMT
AVBP vs FDMT: by the numbers
- •AVBP is the larger company ($724M vs $663M market cap).
- •Both run net losses; AVBP's is the smaller (0.00% vs -194.74% net margin).
Metrics side by side
Valuation
| Metric | AVBP | FDMT |
|---|---|---|
| P/S ratio | N/A | 7.20 |
| P/B ratio | 1.97 | 1.63 |
Profitability
| Metric | AVBP | FDMT |
|---|---|---|
| Gross margin | 0.00% | 91.05% |
| Operating margin | 0.00% | -187.24% |
| Net margin | 0.00% | -194.74% |
| ROE | -44.63% | -43.95% |
| ROIC | -47.96% | -44.30% |
Growth (annualized)
| Metric | AVBP | FDMT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 31.93% |
| Total return CAGR (5Y) | N/A | -13.08% |
Go deeper
Dig into the metrics
ArriVent BioPharma ROE4D Molecular Therapeutics ROEArriVent BioPharma operating margin4D Molecular Therapeutics operating marginArriVent BioPharma revenue growth4D Molecular Therapeutics revenue growthArriVent BioPharma free cash flow4D Molecular Therapeutics free cash flow
ArriVent BioPharma & 4D Molecular Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.